【藥品性質提示】 GFR <30 mL/min 以下之慢性腎臟疾病病人，建議勿處方本品 (NSAID)。

For the short-term treatment of postoperative pain (not more than 4 days)

Following IV or IM injection, parecoxib is rapidly converted to valdecoxib, the pharmacologically active substance, by enzymatic hydrolysis in the liver. Analgesic and antiinflammatory effects of valdecoxib are related to inhibition of prostaglandin synthesis, via inhibition of the cyclooxygenase-2 (COX-2) isoenzyme.

Onset: within 20 min; Duration: 5~8 hrs; Time to peak: <1 hr(IV), 1.5~2.5 hrs(IM ); Plasma protein binding: ∼98%; valdecoxib is a substrate for cytochrome P450 isoenzymes (3A4 and 2C9); it is extensively metabolized via glucuronidation and P450-mediated methyl-group hydroxylation; Elimination half-life of valdecoxib: about 8 hrs.

Previous hypersensitivity to parecoxib or valdecoxib; Acute peptic ulcer disease or GI bleeding; Patients with a history of bronchospasm with rhinoconjunctivitis or urticaria/angioedema associated with aspirin or other nonsteroidal antiinflammatory agents; patients with a history of allergic reactions to sulfonamides; Parecoxib should be avoided in patients with severe hepatic impairment (Child-Pugh score of 10 or more), inflammatory bowel disease, and moderate to severe heart failure (NYHA class II to IV); should not be used in patients with ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease. It should also not be used after coronary artery bypass graft surgery.

C [AUS]

Avoided.

Anaemia, hypokalaemia, agitation, insomnia, pharyngitis, respiratory insufficiency, alveolar osteitis (dry socket), dyspepsia, flatulence, pruritus.

40 mg IV or IM, followed every 12 to 24 hours by 20 mg as required. MAX dose 80 mg/day. Elderly patients weighing less than 50 kg should begin treatment with half the usual dose, repeated to a maximum of 40 mg daily. Doses may need to be reduced in hepatic impairment. Intravenous parecoxib has been given as a bolus over at least 15 seconds.

(Child-Pugh score 5-6) no dose adjustment; (Child-Pugh score 7-9) initiate with 50% of the usual dosage, Max dose: 40mg; (Child-Pugh score≧ 10) avoided.

每vial稀釋液體積：請使用2 ml 之NS、D5W、0.45%G/S預先稀釋；不可以用注射用水(非等張溶液)，Lactated Ringer's solution 稀釋。
靜脈輸注液：NS、D5W、0.45%G/S
給藥方式：靜脈注射、肌肉注射或注入靜脈注射管線（IV line）的方式給藥
注意事項：調配完成之Dynastat注射液應於24小時內使用